New Director Joins LSU Innovation & Technology Commercialization

BATON ROUGE – Department of Innovation and Commercialization of LSU Technologies met the new director Alexei Valiyaev. Valiev is a technology commercialization specialist who has worked in early-stage technology commercialization, identifying, negotiating, and implementing high-value strategic collaborations between universities and industry for the past 12 years. He has international experience in various fields and organizations on three continents and five countries.

“We are excited to bring Alex’s extensive experience in technology commercialization and leadership at LSU to support technology commercialization. Alex will be a great addition to the office and help LSU do some really great things in innovation, ”said Andrew Maas, vice president of technology transfer research and director of the Office of Innovation and Ecosystem Development, who oversees LSU’s Office of Innovation and Technology Commercialization. .

The new director of the Office for Commercialization of Innovation and Technology is Alexei Valiyaev.

– Author: Catherine Segers, LSU

Velyaev has helped many scientists and business researchers raise millions of dollars to fund innovative research and technology development from public and private sources. He negotiated high-value licensing and sponsored research agreements, facilitated alliances with companies, and advised senior academic leadership on strategies to expand partnerships between academia and industry.

“Through years of working in research institutions, I have found that the intersection of new technology development, commercialization, and partnerships with academia benefits both personally and professionally. I am counting on the exceptional services of LSU innovators to help them bring inventions from research laboratories to the market, ”Valiyaev said.

Prior to joining LSU, Valiyev served at Oklahoma State University from 2017 to 2022, where he led the university’s biomedical technology translation and managed diversified intellectual property portfolios in a variety of fields ranging from pharmaceuticals and medical technologies to veterinary drugs and medicines. He helped create a business mentoring program for inventors, fostered interdisciplinary collaboration in technology development, and worked to create startups.

In his previous position at Sydney Medical School, he led the strategic development of new industry partnerships to increase industry revenue and fund clinical research grants. During his tenure at the University of Sydney’s Office of Commercial Development and Industrial Partnership, he organized general cooperation agreements with medical technology and agrochemical companies, as well as licensed various software, biopharmaceutical and defense technologies. There, he worked with university startups, including successful biomedical businesses such as Elastage, which was acquired by Allergan in 2018 for $ 95 million. During 2014-15, he was part of a startup team that developed a new therapy for dry eye, a disease that affects more than 16 million Americans. While in Australia, he was also a co-founder and managed a startup from design to production based on new web printing technology applications.

Prior to joining the technology transfer profession, Vyalyaev worked at Procter & Gamble, where he managed a multimillion-dollar account, building win-win partnerships with major retailers and implementing joint business plans. When he began his career as an engineer in a leading company for the production of scientific instruments, Valiyaev worked internationally, focusing on business development, installation of research equipment and training of clients in Hungary, South Korea and other countries.

He received a bachelor’s degree in electrical engineering from the Moscow State Electronic Technological Institute, where he studied the effect of ion beam treatment on the properties of materials. He received a master’s degree and a doctorate. in Materials Science from Duke University for the study of stimulus-responsive polymers and elastin-like polypeptides. His research has led to several peer-reviewed articles published in leading journals such as Langmuir, Vacuum and the Journal of the American Chemical Society. He is also a registered patent agent of the U.S. Patent and Trademark Office.

“My goals and vision of the Office of Innovation and Technology Commercialization are based on excellence in three main areas: education, relationships and outreach, and productivity. “Education” includes a number of activities aimed at enhancing communication with faculty, staff, and students. “Interaction and Coverage” aims to build strong relationships between LSU and the industry sector, as well as identify opportunities for new technology development, industry partnerships and intellectual property licensing. Finally, “performance” focuses on providing technology transfer services to LSU inventors, raising standard performance metrics for technology transfer, such as number of licenses and options, licensing revenue, new disclosures, patent applications and startups, and helping streamline partnership execution between academia and industry, ”he said.

Leave a Comment